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2 July 2018 Updated Searches updated 2 July 2018; one new study
has been included (Chung 2014).
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Date Event Description
18 June 2013 New citation: conclusions not
changed
One new study added to the review; authors of review
changed.
 
18 June 2013 Updated Search re-run to include head-to-head trials; new
'Summary of findings' table; methods sections
updated.
 
31 August 2012 New citation: conclusions not
changed
Updated search, added additional study and re-ran
analyses including additional side effect analyses.
Additional figure to better demonstrate the dose-
response analysis.
Completed 'Risk of bias' assessment for all included
studies.
Completed 'Summary of findings' table.
Studies added to excluded studies.
MEDLINE search strategy included.
 
24 October 2008 Amended Search strategy amended to comply with RevMan 5
format.
 
24 April 2008 Amended Converted to new review format.
 
24 April 2008 Updated We re-ran our searches on 10 May 2007 - several
potentially relevant studies were found.
 
24 April 2008 New citation: conclusions not
changed
New studies have been added to the 'included',
'excluded' and 'ongoing assessment' sections.
Analysis has been re-run and the text of the study has
been updated to take into account the newly included
studies.
 






The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single
antiepileptic drug. However, up to 20% of patients from population-based studies, and up to 30% from clinical
series (not population-based), develop drug-resistant epilepsy, especially those with focal-onset seizures. In this
review, we summarise the current evidence regarding topiramate, an antiepileptic drug first marketed in 1996,
when used as an add-on treatment for drug-resistant focal epilepsy.
This is an update of a Cochrane Review first published in 1999, and last updated in 2014.
Objectives
To evaluate the efficacy and tolerability of topiramate when used as an add-on treatment for people with drug-
resistant focal epilepsy.
Search methods
For the latest update of this review we searched the following databases on 2 July 2018: Cochrane Register of
Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central
Register of Controlled Trials (CENTRAL); MEDLINE (Ovid, 1946- ); ClinicalTrials.gov and the WHO International
Clinical Trials Registry Platform (ICTRP). We imposed no language restrictions. We also contacted the
manufacturers of topiramate and researchers in the field to identify any ongoing or unpublished studies.
Selection criteria
Randomised, placebo-controlled add-on trials of topiramate, recruiting people with drug-resistant focal
epilepsy.
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Data collection and analysis
Two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the
following outcomes: (1) 50% or greater reduction in seizure frequency; (2) seizure freedom; (3) treatment
withdrawal (any reason); (4) adverse effects. Primary analyses were intention-to-treat (ITT), and summary risk
ratios (RRs) with 95% confidence intervals (95% CIs) are presented. We evaluated dose-response in regression
models. We carried out a 'Risk of bias' assessment for each included study using the Cochrane 'Risk of bias' tool
and assessed the overall certainty of evidence using the GRADE approach.
Main results
We included 12 trials, representing 1650 participants. Baseline phases ranged from four to 12 weeks and
double-blind phases ranged from 11 to 19 weeks. The RR for a 50% or greater reduction in seizure frequency
with add-on topiramate compared to placebo was 2.71 (95% CI 2.05 to 3.59; 12 studies; high-certainty
evidence). Dose regression analysis showed increasing effect with increasing topiramate dose demonstrated by
an odds ratio (OR) of 1.45 (95% CI 1.28 to 1.64; P < 0.001) per 200 mg/d increase in topiramate dosage. The
proportion of participants achieving seizure freedom was also significantly increased with add-on topiramate
compared to placebo (RR 3.67, 95% CI 1.79 to 7.54; 8 studies; moderate-certainty evidence). Treatment
withdrawal was significantly higher for add-on topiramate compared to placebo (RR 2.37, 95% CI 1.66 to 3.37;
12 studies; high-certainty evidence). The RRs for the following adverse effects indicate that they are significantly
more prevalent with topiramate, compared to placebo: ataxia 2.29 (99% CI 1.10 to 4.77; 4 studies); concentration
difficulties 7.81 (99% CI 2.08 to 29.29; 6 studies; moderate-certainty evidence); dizziness 1.52 (99% CI 1.07 to
2.16; 8 studies); fatigue 2.08 (99% CI 1.37 to 3.15; 10 studies); paraesthesia 3.65 (99% CI 1.58 to 8.39; 7 studies;
moderate-certainty evidence); somnolence 2.44 (99% CI 1.61 to 3.68; 9 studies); 'thinking abnormally' 5.70 (99%
CI 2.26 to 14.38; 4 studies; high-certainty evidence); and weight loss 3.99 (99% CI 1.82 to 8.72; 9 studies; low-
certainty evidence). Evidence of publication bias for the primary outcome was found (Egger test, P = 0.001). We
rated all studies included in the review as having either low or unclear risk of bias. Overall, we assessed the
evidence as moderate to high certainty due to the evidence of publication bias, statistical heterogeneity and
imprecision, which was partially compensated for by large effect sizes.
Authors' conclusions
Topiramate has efficacy as an add-on treatment for drug-resistant focal epilepsy as it is almost three times more
effective compared to a placebo in reducing seizures. The trials reviewed were of relatively short duration and
provided no evidence for the long-term efficacy of topiramate. Short-term use of add-on topiramate was shown
to be associated with several adverse events. The results of this review should only be applied to adult
populations as only one study included children. Future research should consider further examining the effect of
dose.
Plain language summary
Topiramate add-on for drug-resistant focal epilepsy
Background
Epilepsy is a disorder where recurrent seizures are caused by abnormal electrical discharges from the brain. Most
seizures can be controlled by a single antiepileptic drug. Unfortunately, some people require more than one
antiepileptic medication to control their seizures, especially if these originate from one area of the brain (focal
epilepsy), instead of affecting the entire brain (generalised epilepsy). These people are said to have drug-
resistant epilepsy. Topiramate can be used in addition to other antiepileptic drugs, called an add-on treatment,
to try to control drug-resistant epilepsy.
Aim of this review
This review investigated the effectiveness and tolerability of topiramate when used as an add-on treatment for
people with drug-resistant focal epilepsy.
Results
We found 12 trials that investigated topiramate as an add-on treatment. They included a total of 1650 people
with drug-resistant focal epilepsy. These trials compared the antiepileptic drug topiramate to a placebo drug (an
inactive, dummy drug which should not show any effect) for a period of up to 18 weeks. Taking all the evidence
of the trials into account, the review found that topiramate is almost three times more effective, when used with
other drugs, at reducing the number of seizures in drug-resistant focal epilepsy than placebo. Adding topiramate
to people's usual treatment was, however, associated with an increase in adverse effects such as problems with
co-ordination (ataxia), concentration, dizziness, drowsiness (somnolence), fatigue, 'thinking abnormally', tickling
or numbness of the skin (paraesthesia) and weight loss. People taking add-on topiramate were also more than
twice as likely to withdraw from treatment than those taking placebo, most likely due to adverse effects.
Certainty of the evidence
We assessed the trials with regards to potential bias and certainty. Overall, we rated the certainty of the evidence
as moderate to high which means that we are fairly certain that the findings that we have reported are accurate.
The trials included in this review did not examine the long-term effects of topiramate as an add-on treatment
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and only one study investigated the use of add-on topiramate in children. The findings should, therefore, only be
applied to adults with drug-resistant focal epilepsy. Future research should test which dose is most effective.
The evidence is current to July 2018.
Background 
This is an update of a Cochrane Review first published in 1999 (Jette 1999b), and last updated in 2014 (Pulman
2014). The purpose of this update is to synthesise the current data in order to understand the role of topiramate
as an add-on treatment in drug-resistant focal epilepsy. For the purpose of this review, people with drug-
resistant focal epilepsy have been defined as having focal-onset seizures (simple focal and/or complex focal
seizures and/or secondary generalised tonic-clonic seizures) that have failed to respond to at least one
monotherapy treatment with a standard antiepileptic drug.
Description of the condition
The majority of people given a diagnosis of epilepsy have a good prognosis and their seizures are
controlled by treatment with a single antiepileptic drug (Kwan 2000; Reynolds 1981), but up to 20% of
patients from population-based studies, and up to 30% from clinical (non population-based) series, will
develop drug-resistant epilepsy (Cockerell 1995; Kwan 2000), often requiring treatment with combinations
of antiepileptic drugs. This presents a significant therapeutic problem when approximately 1% of the general
population will suffer from epilepsy at some point in their lifetime (Fiest 2017).
Description of the intervention
Over the past decade, there has been renewed interest in the development of newer antiepileptic drugs. This is
largely because several of the standard antiepileptic drugs are not always successful at controlling seizures, and
because some have been associated with certain adverse effects. In the first instance, new antiepileptic drugs are
tested as an add-on treatment for people with drug-resistant focal epilepsy in randomised controlled trials
(RCTs). Having demonstrated a therapeutic effect in these trials, new antiepileptic drugs tend to be licensed for
add-on use before monotherapy trials have been undertaken, in which new antiepileptic drugs are compared
with standard ones.
How the intervention might work
There are an ever increasing number of licensed antiepileptic drugs from which to choose from, for
people with drug-resistant focal epilepsy. This review focuses upon the effects of topiramate, a drug
whose mechanisms of action include a modulatory effect on voltage-dependent sodium conductance (Coulter
1993), enhancement of gamma-aminobutyric acid-A (GABAA)-mediated chloride flux (Brown 1993),
antagonism of kainate receptor-mediated excitatory currents (Gryder 2003), and inhibition of carbonic
anhydrase, an enzyme necessary for GABAergic neurotransmission (Herrero 2002). Topiramate was licensed for
add-on use in the UK in 1996.
Why it is important to do this review
In this review, we summarise evidence from RCTs which have investigated the effects of topiramate in people
with drug-resistant focal epilepsy in order to aid clinical decision-making when prescribing antiepileptic drug
treatments within this population.
Objectives 
To evaluate the efficacy and tolerability of topiramate when used as an add-on treatment for people with drug-
resistant focal epilepsy.
Methods 
Criteria for considering studies for this review 
Types of studies 
Studies had to meet all of the following criteria.
RCTs1.
Double- or single-blinded trials2.
Placebo-controlled3.
Parallel-group or cross-over studies4.
Minimum treatment period of eight weeks5.
Types of participants 
People of any age with drug-resistant focal epilepsy (i.e. experiencing simple focal, complex focal or secondarily
generalised tonic-clonic seizures).
Types of interventions 
The active treatment group received treatment with topiramate in addition to conventional antiepileptic drug1.
treatment.
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The control group received a matched placebo or an alternative dose of topiramate in addition to conventional2.
antiepileptic drug treatment.
Types of outcome measures 
Primary outcomes
50% or greater reduction in seizure frequency
The primary outcome is the proportion of people with a 50% or greater reduction in seizure frequency in the
treatment period compared to the pre-randomisation baseline period. This outcome was chosen as it is
commonly reported in this type of study. Furthermore, this outcome can also be calculated for studies which
report baseline and follow-up seizure frequencies.
Secondary outcomes
Seizure freedom
The proportion of people with complete cessation of seizures during the treatment period.
Treatment withdrawal
The proportion of people having treatment withdrawn during the course of the treatment period was used as a
measure of 'global effectiveness'. Treatment is likely to be withdrawn due to adverse effects, lack of efficacy or a
combination of both, and this is an outcome to which participants make a direct contribution. In trials of short
duration, it is likely that adverse effects will be the most common reason for withdrawal.
Adverse effects












We chose these adverse effects as we considered them to be common and important adverse effects of
antiepileptic drugs.
Search methods for identification of studies 
Electronic searches 
We ran searches for the original review on 18 June 2013, and subsequent searches in August 2016 and
November 2016. For the latest update, we searched the following databases on 2 July 2018.
Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and1.
the Cochrane Central Register of Controlled Trials (CENTRAL), using the strategy outlined in Appendix 1.
MEDLINE (Ovid, 1946- ) using the strategy outlined in Appendix 2.2.
ClinicalTrials.gov using the strategy outlined in Appendix 3.3.
WHO International Clinical Trials Registry Platform (ICTRP) using the strategy outlined in Appendix 4.4.
There were no language restrictions.
Previously we also searched SCOPUS (1823 to 18 June 2013) as an alternative to Embase, using the strategy
outlined in Appendix 5. This is no longer necessary, because randomised and quasi-randomised controlled trials
in Embase are now included in CENTRAL, so the SCOPUS search has not been updated.
Searching other resources 
We reviewed reference lists of included studies to search for additional reports of relevant studies and contacted
Johnson and Johnson for information about any unpublished or ongoing studies.
Data collection and analysis 
Selection of studies 
For the update, two review authors (RB and JH) independently assessed trials for inclusion. Any disagreements
were resolved by discussion with a third review author (AGM). Two review authors (RB and JH) extracted data and
assessed risk of bias; disagreements again were resolved by discussion.
Data extraction and management 
We extracted the following information for each trial using a data extraction form.
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Methodological/trial design
Method of randomisation and allocation concealment1.
Method of blinding2.
Whether any participants had been excluded from reported analyses3.
Length of baseline period4.
Length of treatment period5.
Dose(s) of topiramate tested6.
Patient/demographic information
Total number of participants allocated to each treatment group1.
Age/sex2.
Number with focal/generalised epilepsy3.
Seizure types4.
Seizure frequency during the baseline period5.
Number of background drugs6.
Most of the trials found were sponsored by Johnson and Johnson who were asked to confirm the following
information.
Method of randomisation1.
Total number randomised to each group2.
Number of participants in each group achieving a 50% or greater reduction in seizure frequency per treatment3.
group
Number of participants having treatment withdrawn post-randomisation per treatment group4.
For those excluded:5.
the reason for exclusion;a.
whether any of those excluded completed the treatment phase;b.
whether any of those excluded had a 50% or greater reduction in seizure frequency during the treatmentc.
phase.
Outcomes
We recorded the number of people experiencing each outcome (see Types of outcome measures) per randomised
group. We contacted authors of trials for any missing information.
Assessment of risk of bias in included studies
Two review authors (RB and JH) independently made an assessment of the risk of bias for each trial using the
Cochrane 'Risk of bias' tool as described in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We discussed and resolved any disagreements. We rated the included studies as high risk, low
risk or unclear risk for the six domains applicable to RCTs: randomisation method, allocation concealment,
blinding methods, incomplete outcome data, selective outcome reporting and other sources of bias.
We created 'Summary of findings' tables, and employed the GRADE approach for assessing certainty of evidence.
Measures of treatment effect
We presented the primary outcome, 50% or greater reduction in seizure frequency, and the secondary outcomes,
seizure freedom and treatment withdrawal, as risk ratios (RRs) with 95% confidence intervals (CIs). For the
reporting of the individual adverse effects, we again presented the results as RRs, but instead quoted 99% CIs to
compensate for multiple testing. By contrast, we reported the results from the dose regression model as odds
ratios (ORs) with 95% CIs.
Unit of analysis issues 
There were no unit of analysis issues.
Dealing with missing data
We sought any missing data from the study authors. We carried out intention-to-treat (ITT), best-case and
worst-case analysis on the primary outcome to account for any missing data. All analyses are presented in the
main report.
Assessment of heterogeneity 
We assessed clinical heterogeneity by comparing the distribution of important individual participant factors
among trials (for example, age, seizure type, duration of epilepsy, number of antiepileptic drugs taken at the
time of randomisation) and trial factors (for example, randomisation concealment, blinding, losses to follow-
up). We examined statistical heterogeneity using a Chi2 test and the I2 statistic for heterogeneity and, providing
no heterogeneity was present (P > 0.10), we employed a fixed-effect model. In the event that heterogeneity was
found, we planned to use a random-effects model analysis using the inverse-variance method.
Assessment of reporting biases
We requested all protocols from study authors to enable a comparison of outcomes of interest. Outcome
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reporting bias was to be investigated using the ORBIT matrix system (Kirkham 2010). We also undertook visual
examination of funnel plots as well as the Egger test, a statistical test to determine publication bias in meta-
analyses, to establish any publication bias.
Data synthesis
We employed a fixed-effect model meta-analysis to synthesise the data for the comparison, topiramate versus
placebo, for the outcomes:




Each outcome was to be stratified by study characteristics to ensure the appropriate combination of study data.
Our preferred estimator was the Mantel-Haenszel RR. For the outcomes 50% or greater reduction in seizure
frequency and treatment withdrawal, we used 95% CIs. For individual adverse effects we used 99% CIs to make an
allowance for multiple testing.
Our analyses included all participants in the treatment group to which they had been allocated. For the efficacy
outcome, 50% or greater reduction in seizure frequency, we undertook three analyses, two of which were
sensitivity analyses:
Primary (ITT) analysis: participants from both treatment groups not completing follow-up or with inadequate1.
seizure data were assumed to be non-responders.
Worst-case analysis (sensitivity analysis): participants not completing follow-up or with inadequate seizurea.
data were assumed to be non-responders in the intervention (topiramate) group, but were assumed to be
responders in the placebo group.
Best-case analysis (sensitivity analysis): participants not completing follow-up or with inadequate seizureb.
data were assumed to be responders in the intervention (topiramate) group, but were assumed to be non-
responders in the placebo group.
The best-case and worst-case analyses served to determine whether the assumption made during ITT analysis
(i.e. that all participants not completing follow-up or with inadequate seizure data are non-responders) grossly
affected the estimated effect size.
Dose regression analysis
For the primary outcome, we examined the dose-response relationship using a generalised linear mixed model
with the xtmelogit in STATA SE version 14. The binary outcome was defined with the value '0' for patients who
did not achieve a 50% or greater reduction in seizure frequency and was defined as the value '1' for patients who
did. Study and dose were included as a fixed-effect and a random-effect was included for the treatment (no
random-effect for the constant term), as described in Turner 2000. Dose was standardised by its standard
deviation (351.9 mg/d). This method estimated an OR as opposed to a RR. We then used the command,
meqrlogit, to predict the probabilities for the following: (i) the percentage of patients having a 50% response at
differing doses; (ii) the difference in the percentage of patients responding to each dose compared to placebo.
Subgroup analysis and investigation of heterogeneity 
We undertook subgroup analysis for adverse effects. We intended to investigate heterogeneity using sensitivity
analysis if deemed appropriate.
Sensitivity analysis
We conducted five forms of sensitivity analyses in total during the data synthesis. Two such sensitivity analyses
were highlighted and explained earlier, best- and worst-case analysis (see Data synthesis). We also intended to
carry out sensitivity analysis if peculiarities were found between study quality, characteristics of participants,
interventions and outcomes. Specifically, we detected heterogeneity in the outcome, 50% or greater reduction in
seizure frequency, and, therefore, we applied the following sensitivity analysis according to: study quality (we
excluded studies with either high or unclear risk of bias) and age (we excluded one study because it included
paediatric participants). Finally, we conducted a sensitivity according to dosage. We excluded three studies
because all three only assessed dose of 200 mg/d topiramate.
Summarising and interpreting results using GRADE
We used the GRADE approach, as outlined in the GRADE Handbook (Schünemann 2013), to assess the
certainty of evidence and to interpret findings. We used GRADEpro GDT software (GRADEpro GDT 2015),
which imports data from Review Manager 5 software (Review Manager 2014), to create a 'Summary of findings'
table for the following outcomes: 50% or greater reduction in seizure frequency, seizure freedom, treatment
withdrawal, weight loss/decrease, paraesthesia, thinking abnormally, and difficulty with concentration.
Results 
Description of studies 
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Results of the search
The search revealed 1346 records identified from the databases, outlined in Electronic searches. After removing
541 duplicates, 805 records remained and we screened all for inclusion in the review. We excluded 758 records
at this point due to irrelevance, leaving 46 records to be assessed for eligibility at the full-text stage of
screening. Following this, we excluded five studies, linked to seven individual records (see Figure 1 and
Characteristics of excluded studies for reasons of exclusion). We included a total of 12 studies (linked to 37
individual records) in the review, all of which we included in meta-analyses. We identified two abstracts (two
records) as studies awaiting classification and contacted the authors of these studies for more information. At
the time of publication, no correspondence had been received.
Included studies
The 12 RCTs identified by the screening process recruited a total of 1650 participants and between them tested
doses of 200 mg, 300 mg, 400 mg, 600 mg, 800 mg and 1000 mg topiramate per day. For further information
on each trial, see Characteristics of included studies.
Overall, there were 10 randomised controlled trials (RCTs) which compared topiramate to placebo in adults
aged 18 to 75 years (Ben-Menachem 1996; Chung 2014; Faught 1996; Guberman 2002; Korean Topiramate
Study Group 1999; Privitera 1996; Rosenfeld 1996; Sharief 1996; Tassinari 1996; Yen 2000), one RCT
which examined topiramate versus a placebo in children (Elterman 1999), and one other RCT which
examined the same comparison within the elderly (Zhang 2011). Eight of these trials were sponsored by Johnson
and Johnson. In all of the trials, participants were eligible to take part in the double-blind part of the trials if they
were found to experience a minimum number of focal seizures (range 3 to 12 seizures) and were currently taking
one to two or one to three antiepileptic drug treatments. See Table 1 for comparison of study characteristics.
One multicentre, parallel trial had a pre-randomisation period of eight weeks and a treatment period of 13
weeks (Ben-Menachem 1996), randomising 56 adults to one of two treatment arms: 800 mg of topiramate (n =
28) or placebo (n = 28). The study medication was administered twice daily or to the maximal tolerated dose.
Similarly, a multicentre, parallel trial had a pre-randomisation baseline period of eight weeks (Chung 2014). This
trial featured a shorter treatment period of 11 weeks and consisted of two treatment arms. Two hundred and
forty-nine participants were randomised to either placebo (n = 125) or 200 mg/d topiramate (n = 124).
The Elterman 1999 multicentre (USA, Costa Rica), parallel trial, randomised 41 children aged one to 16 years to
topiramate and 45 to placebo. Participants were eligible if they experienced six or more seizures during baseline
and were taking one or two antiepileptic drugs. The baseline period was eight weeks in duration with a treatment
period of 16 weeks.
Another parallel trial from the USA had three different treatment arms and a placebo arm (Faught 1996). Forty-
five adults aged 18 to 65 years were randomised to 200 mg per day of topiramate, 45 mg to 400 mg per day
topiramate or 46 mg to 600 mg per day topiramate and 45 were randomised to the placebo group. This trial had
a baseline period of 12 weeks and a treatment period of 16 weeks.
A further multicentre, parallel trial (Guberman 2002), randomised adults to one of three treatment arms:
topiramate escalated weekly by 25 mg to 200 mg per day (n = 85), topiramate escalated weekly by 50 mg to 200
mg per day (n = 83), and placebo (n = 91). This trial had a baseline period of four weeks and a titration period of
eight weeks for the 25 mg group or four weeks for the 50 mg group. The double-blind treatment phase was 12
weeks in duration.
The parallel trial run by the Korean Topiramate Study Group (Korean Topiramate Study Group 1999), investigated
adults only and consisted of two main treatment arms including 600 mg topiramate (n = 91) and placebo (n =
86). The baseline period was 12 weeks in duration followed by a titration period of 10 weeks and then a
stabilisation period of eight weeks.
A multicentre, parallel trial had a 12-week baseline period followed by an 18-week double-blind
treatment period (Privitera 1996). Within this phase was a six-week titration period and 12-week stabilisation
period. Adults were randomised to one of four treatment arms: 48 mg to 600 mg per day topiramate, 48 mg to
800 mg per day topiramate, 47 mg to 1000 mg per day topiramate and 47 were randomised to placebo.
Another multicentre, parallel trial had an eight-week baseline period and a 19-week treatment period (
Rosenfeld 1996). Two hundred and nine adults were randomised to one of two treatment arms in a ratio of 1:3,
resulting in 42 patients being randomised to placebo and 167 patients being randomised to 1000 mg per day
topiramate.
Another multicentre, parallel trial had a pre-randomisation period of eight weeks and a treatment period
of 11 weeks (Sharief 1996), where 23 adults were randomised to 400 mg per day topiramate and 24 were
randomised to placebo. At the target dose, medication was administered twice daily.
The parallel trial by Tassinari 1996 was a multicentre trial in which adults were randomised to one of two
treatments arms: 600 mg topiramate (n = 30) and placebo (n = 30). The baseline period was eight weeks
followed by a treatment period of 12 weeks.
One single-centre, parallel trial in China had a baseline period of eight weeks and a treatment period of 14
weeks (Yen 2000), and randomised 23 adults to 300 mg per day topiramate and 23 to placebo.
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One study included elderly patients (aged over 65) only and had two treatment arms (Zhang 2011): 200 mg per
day topiramate (n = 46) or placebo (n = 40). The baseline period for this study was eight weeks in duration
followed by a titration phase of eight weeks and then a treatment period of 12 weeks.
Excluded studies
We excluded five RCTs for the following reasons: two studies had no placebo control group (Christensen 2003; 
Ramsay 2008), one study was an active comparator-controlled trial (Chung 2009), one study had a
baseline period of 48 hours (Novotny 2010), and one study did not investigate any of the outcomes under
review (Coles 1999). For further information regarding exclusion, see Characteristics of excluded studies.
Studies awaiting classification
We were unable to include a further two studies in the review as we unsure about their eligibility for
inclusion (Aranguiz 1991; Kazibutowska 2000). We attempted to contact the authors for additional information
to allow for the classification of the studies, but no correspondence had been received at the time of publication.
For details regarding these studies, see Characteristics of studies awaiting classification.
Risk of bias in included studies 
We allocated each study a rating for each risk of bias domain. All studies included in the review were rated as
having either low risk of bias or unclear risk of bias across all domains. Below, the specific domain ratings are
explained.
See 'Risk of bias' tables within the Characteristics of included studies tables for further details. See Figure 2 for a
summary of the risk of bias in each included study and Figure 3 for a summary of each domain across studies.
Allocation (selection bias)
For the domain of random sequence generation, we rated 11 studies as low risk of bias due to the use of a
computer-generated randomisation schedule or the use of random number tables/random permuted blocks
(Ben-Menachem 1996; Chung 2014; Elterman 1999; Faught 1996; Korean Topiramate Study Group 1999; 
Privitera 1996; Rosenfeld 1996; Sharief 1996; Tassinari 1996; Yen 2000; Zhang 2011). We rated one
study as unclear due to a lack of detail provided regarding the methods used (Guberman 2002).
In addition, we rated the methods by which allocation was concealed in 10 of the included studies as low
risk of bias (Ben-Menachem 1996; Chung 2014; Elterman 1999; Faught 1996; Korean Topiramate Study Group
1999; Privitera 1996; Rosenfeld 1996; Sharief 1996; Tassinari 1996; Yen 2000). Nine of the studies used
sealed, numbered packages, allocated sequentially, to conceal allocation (Ben-Menachem 1996; Elterman 1999; 
Faught 1996; Korean Topiramate Study Group 1999; Privitera 1996; Rosenfeld 1996; Sharief 1996; Tassinari
1996; Yen 2000), and one more recent trial used an interactive voice response system (Chung 2014).
Two trials did not provide clear methods and we thus rated them as having unclear risk of bias for this
domain (Guberman 2002; Zhang 2011).
Blinding (performance bias and detection bias)
In all but one study, successful blinding of participants was achieved by using identical medication within
the topiramate and placebo groups (Ben-Menachem 1996; Chung 2014; Elterman 1999; Faught 1996; 
Guberman 2002; Korean Topiramate Study Group 1999; Privitera 1996; Rosenfeld 1996; Sharief 1996; Tassinari
1996; Yen 2000); we judged these 11 studies at low risk of performance bias. There were no details reported by
Zhang 2011, and so we rated this study as having unclear risk of bias. The blinding of the outcome assessor
was difficult to judge due to the lack of detail in 10 of the publications (Ben-Menachem 1996; Chung 2014; 
Elterman 1999; Faught 1996; Guberman 2002; Korean Topiramate Study Group 1999; Privitera 1996; Rosenfeld
1996; Tassinari 1996; Zhang 2011) and, therefore, we rated these studies as having unclear detection
bias. We rated the other two studies at low risk of bias for this particular domain (Sharief 1996; Yen 2000), as the
two studies specified that outcome assessors remained blinded.
Incomplete outcome data (attrition bias)
We rated all studies at low risk of bias for this domain due to the ITT analyses undertaken by the study authors.
Selective reporting (reporting bias)
We requested the protocols for all included studies to compare a priori methods and outcomes to the published
report but the majority of these were unavailable. We rated all included studies as low risk of bias for this domain
as there was no suspicion of selective outcome reporting bias; all expected outcomes were reported in each of
the publications.
Other potential sources of bias
We rated all studies at low risk of bias for this domain as we did not detect any further bias in any of the included
studies.
Effects of interventions 
See Summary of findings table 1 for a summary and GRADE assessment of the primary and secondary outcomes.
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50% or greater reduction in seizure frequency
Intention-to-treat (ITT) analysis
Data from all 12 studies and including 1650 participants contributed to this outcome. A Chi2 test for
heterogeneity in a response to topiramate showed significant heterogeneity between trials (Chi² = 18.29, df =
11, P = 0.07, I² = 40%), therefore we employed a random-effects model. The overall risk ratio (RR) for a response
to topiramate compared to placebo using the random-effects model was 2.71 (95% confidence interval (CI) 2.05
to 3.59; 12 studies, 1650 participants; high-certainty evidence; Analysis 1.2), indicating that participants
receiving add-on topiramate were nearly three times more likely to have a 50% or greater reduction in seizure
frequency than those receiving add-on placebo.
As a result of the significant heterogeneity detected, we conducted three separate sensitivity analyses. Firstly, we
noted that the studies included in the analysis for this outcome varied with regards to the overall risk of bias
awarded. We thus completed a sensitivity analysis by study quality by only including studies associated with low
risk of bias overall. Following this sensitivity analysis, the RR increased to 4.36 (95% CI 2.24 to 8.50) and there
was no longer any detectable statistical heterogeneity (Chi² = 0.13, df = 2, P = 0.94, I² = 0%; Analysis 1.1
). We similarly conducted a sensitivity analysis according to patient characteristics. For this, we excluded
one study from the analysis because it studied a paediatric study population and all other studies were
conducted in adults (Elterman 1999). The exclusion of this study did not resolve the detected heterogeneity (Chi²
= 17.94, df = 10, P = 0.06, I² = 44%) and did not greatly impact the estimated RR (RR 2.85, 95% CI 2.09 to 3.88;
Analysis 1.3). Finally, we conducted a sensitivity analysis according to intervention, during which we
excluded three studies (Chung 2014; Guberman 2002; Zhang 2011). The three excluded studies only assessed
the lowest dosage of topiramate (200 mg/d). Again, heterogeneity was no longer detected amongst the data set
(Chi² = 7.29, df = 8, P = 0.51, I² = 0%), however, the effect estimate remained statistically significant and was
unsurprisingly slightly higher than that detected when all studies were included (RR 3.32, 95% CI 2.51 to 4.38;
Analysis 1.4). We did not conduct a sensitivity analysis according to outcome as this was not deemed
appropriate.
Best- and worst-case scenarios
We again used a random-effects model for both the best-case and worst-case analyses due to the significant
heterogeneity detected (Chi² = 20.93, df = 11, P = 0.03, I² = 47%; Analysis 1.5; and Chi² = 18.97, df = 11, P =
0.06, I² = 42%; Analysis 1.6, respectively). The overall best-case RR scenario for a response to topiramate was RR
3.54 (95% CI 2.67 to 4.69), whilst the worst-case RR scenario was 1.96 (95% CI 1.54 to 2.50). Importantly, all
three analyses for the outcome, 50% or greater seizure reduction, suggest a significant treatment effect for add-
on topiramate compared to add-on placebo (P < 0.00001).
Dose-response regression
We fitted a generalised linear mixed model to the data provided in Analysis 1.2 to estimate the effect of dose on
the primary outcome, 50% or greater reduction in seizure frequency (details in Data synthesis). To include the
data extracted from the study by Elterman 1999, which only recruited children, the daily dose was approximated
by assuming an average adult weight of 75 kg, multiplied by the study dose of 6 mg/kg/day, to give 450 mg/day
topiramate. It was not necessary to conduct any more dose adjustments for the other included studies. The study
by Zhang 2011 only recruited elderly patients, above 65 years of age, and the remaining studies all recruited
patients from adult populations. Doses ranged between 200 mg/day and 1000 mg/day topiramate. In order to
use this model, the dose was standardised by its standard deviation (352 mg). Importantly, the method used
estimated an OR as opposed to a RR.
The OR for a 50% or greater reduction in seizure frequency per 200 mg/d increase in topiramate dose was 1.45
(95% CI 1.28 to 1.64; P < 0.001), with estimated between-study standard deviation of 0.54 (standard error (SE)
0.16), thus revealing that patients were significantly more likely to attain a 50% or greater seizure reduction if
their dose was increased by 200 mg/d (P < 0.001). Notably, the odds of a patient achieving a 50% or greater
reduction in seizure frequency were nearly doubled (OR 1.92, 95% CI 1.54 to 2.40; P < 0.001) when their dose of
topiramate was increased by 350 mg/d, the standard deviation of the included doses (P < 0.001).
The estimated response rate (the percentage of participants achieving a 50% or greater reduction in seizure
frequency) per dose, as well as the estimated increase in response rate compared to placebo for each dose are
given in Table 2. The estimated response rate on placebo was 17.8% (95% CI 6.3% to 29.4%), whereas the
estimated response rate for topiramate ranged from 37.6% to 51.1%, dependent on dose (Table 2). Accordingly,
the estimated response rate per dose compared to placebo ranged from 19.7% for participants randomised to
200 mg/day topiramate up to 33.3% for participants randomised to 1000 mg/day. Both the estimated fitted
response rate and the difference in response rate compared to placebo generally increased with dosage, as would
be expected from the dose-response relationship demonstrated.
Seizure freedom
A Chi2 test for heterogeneity showed no significant heterogeneity between trials (Chi² = 1.84, df = 6, P = 0.93, I²
= 0%). The overall RR for seizure freedom was 3.67 (95% CI 1.79 to 7.54; 8 studies, 1177 participants; moderate-
certainty evidence; Analysis 1.7), indicating that participants randomised to add-on topiramate were over three
times more likely to attain seizure freedom than participants randomised to add-on placebo.
0010 Topiramate add-on therapy for drug-resistant focal epilepsy
10 / 41
Treatment withdrawal
Data from 12 studies, consisting of 1650 participants, contributed to this outcome. A Chi2 test for heterogeneity
demonstrated no significant statistical heterogeneity (Chi² = 8.76, df = 10, P = 0.55, I² = 0%). The overall RR
(95% CI) for withdrawal for any reason was 2.37 (95% CI 1.66 to 3.37; 12 studies, 1650 participants; high-
certainty evidence; Analysis 1.8), thus highlighting that participants were significantly more likely to withdraw
from topiramate than placebo.
Adverse effects
The RRs for adverse effects were as follows (Analysis 1.9).
Ataxia: 2.29 (99% CI 1.10 to 4.77; 4 studies; 757 participants)1.
Concentration difficulties: 7.81 (99% CI 2.08 to 29.29; 6 studies; 702 participants)2.
Dizziness: 1.52 (99% CI 1.07 to 2.16; 8 studies; 1385 participants)3.
Fatigue: 2.08 (99% CI 1.37 to 3.15; 9 studies; 1092 participants)4.
Headache: 0.96 (99% CI 0.67 to 1.39; 10 studies; 1427 participants5.
Nausea/vomiting: 1.50 (99% CI 0.71 to 3.15; 4 studies; 492 participants)6.
Paraesthesia: 3.65 (99% CI 1.58 to 8.39; 7 studies; 1071 participants)7.
Somnolence: 2.44 (99% CI 1.61 to 3.68; 9 studies; 1462 participants)8.
Speech difficulty: 3.37 (99% CI 0.80 to 14.13; 3 studies; 310 participants)9.
Thinking abnormally: 5.70 (99% CI 2.26 to 14.38; 4 studies; 640 participants)10.
Weight loss/decrease: 3.99 (99% CI 1.82 to 8.72; 9 studies; 1070 participants)11.
Collectively, the results imply that receiving add-on topiramate is associated with a higher incidence rate for
many adverse effects compared to add-on placebo. Specifically, add-on topiramate was associated with a
significantly higher incidence rate for the following adverse effects: ataxia (P = 0.003), concentration difficulties
(P < 0.001), dizziness (P = 0.002), fatigue (P < 0.001) , paraesthesia (P < 0.001), somnolence (P < 0.001),
speech difficulty (P = 0.03), 'thinking abnormally' (P < 0.001), and weight loss (P < 0.001), although to differing
degrees of effect. For example, the incidence rate for dizziness was increased by a modest 50% when receiving
add-on topiramate, whereas the incidence rate for 'thinking abnormally' was almost six times greater with add-
on topiramate than with placebo. Notably, however, add-on topiramate did not incur a statistically significant
increase in the risk of experiencing headache (RR 0.96, 99% CI 0.67 to 1.39; 9 studies; 1092 participants; P =
0.79) or nausea (RR 1.50, 99% CI 0.71 to 3.15; 4 studies; 492 participants; P = 0.16) compared to placebo.
Discussion 
Summary of main results
The 12 trials included in this review were all double-blinded and the majority expressly used adequate methods
of allocation concealment. All analyses were by intention-to-treat (ITT). Results from the overall efficacy analysis
show that topiramate is effective in reducing seizure frequency by at least 50% when used as an add-on drug for
people with drug-resistant focal epilepsy. Topiramate was found to be almost three times more effective than a
placebo drug. Even the lowest dose, 200 mg per day, results in nearly 20% more patients achieving a 50%
reduction in seizure rate than placebo. The dose regression model shows increasing effect with increasing dose,
though the increase is quite modest. For people taking 200 mg to 1000 mg per day, results indicate a response
rate of between 38% (95% confidence interval (CI) 20.2 to 55.0) and 51% (95% CI 29.5 to 72.7), an improvement
over placebo of 20% (CI -1.2 to 40.6) to 33% (CI 8.8 to 57.8).
We suspected evidence of publication bias on examination of a funnel plot for the outcome, 50% or greater
reduction in seizure frequency, plus we detected statistical heterogeneity in the data set. The heterogeneity could
be explained by both study quality (excluding studies associated with unclear risk of bias) and by topiramate
dosage. Specifically, statistical heterogeneity was no longer detected when studies which only investigated the
lowest dosage of topiramate (200 mg) were excluded from the analysis. This generates further support for the
observed dose-response relationship as it suggests that lower dosage give a significantly different effect
estimate compared to higher dosages, such that it generates methodological heterogeneity within the data set.
For seizure freedom, the results estimate that topiramate is over three times more likely to be effective in
stopping seizures completely, than a placebo drug. Only half of the included studies reported data on this
outcome, however, and, as a result, this finding must be interpreted with caution.
Results for the outcome, treatment withdrawal, showed that participants are significantly more likely to withdraw
from treatment with add-on topiramate than add-on placebo. In trials of relatively short duration, such as those
reviewed here, treatment withdrawal is likely to represent problems with tolerability rather than poor seizure
control. With respect to adverse events, most of those investigated were significantly more likely to occur in the
topiramate-treated group, except for headache and nausea and vomiting. The risk ratio (RR) for the significant
adverse effects ranged from a low of 1.52 for dizziness to a high of 7.81 for impaired concentration. Although
many of the adverse effects were significantly more likely with add-on topiramate, there was not sufficient
information to determine whether this could be attributed to studies using higher doses.
Overall completeness and applicability of evidence
Primarily, this review aimed to determine the efficacy of topiramate as add-on treatment for people of
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any age with drug-resistant focal epilepsy. Markedly, however, the majority of the data were obtained
from adults aged 16 to 65 years old. Only one study specifically evaluated the use of add-on topiramate
in children, aged 2 to 16 years (Elterman 1999), and, equally, only one study investigated its use in the elderly
(over 65 years old; Zhang 2011). Consequently, the findings presented here cannot be easily generalised to all
age groups and are, instead, largely representative of the effect of add-on topiramate in adults.
Similarly, although the results of this review indicate that topiramate is likely an effective add-on treatment with
regard to seizure reduction, this review cannot tell us how topiramate compares with other antiepileptic drugs in
this scenario. This is an extremely important issue for clinicians who are faced with an ever-increasing number of
antiepileptic drugs to choose from. Head-to-head trials are needed to provide the evidence that is necessary to
enable clinicians to make an evidence-based choice between antiepileptic drugs and their inclusion should be
considered for future review updates.
Moreover, with the possibility of publication bias, we cannot be completely certain that we have identified all
placebo-controlled trials evaluating add-on topiramate. The suspected publication bias suggests that there could
be several small studies, possibly with negative results, which have remained unpublished and that may not have
been highlighted by our searches. This generates uncertainty in our finding that add-on topiramate is more
effective than placebo. The implications of this are addressed further in the subsequent subsections.
Additionally, this review focuses on the use of topiramate in drug-resistant focal epilepsy. The results cannot,
therefore, be generalised to add-on treatment for generalised epilepsies. Likewise, no inference can be made
about the effects of topiramate when used as monotherapy.
Certainty of the evidence
Out of the 12 included studies, we rated all but three of the studies as having unclear risk of bias. We rated the
other three studies as having low risk of bias. Taking all the studies together, we rated the overall risk of bias as
low and considered the evidence to be methodologically sound. The most common issue to generate risk of bias
was the blinding of outcome assessors. Nine of the included studies did not provide explicit details on the
blinding of outcome assessors, however, given the self-report aspect of the outcomes measured, i.e. seizure
frequency and adverse effects experienced, the blinding of outcome assessors was deemed to have minimal
impact on the effect size estimated, hence the overall assessment of low risk of bias.
We employed the GRADE approach to rate the level of certainty of evidence per outcome, the results of which are
presented in Summary of findings table 1. We did not downgrade any of the outcomes for risk of bias, as
reasoned above. For the main outcome of 50% or greater seizure reduction, we rated the certainty of
evidence as high. We downgraded the evidence for 50% or greater seizure reduction once due to the
influence that publication bias may have had on the overall effect estimate. Specifically, a lack of symmetry
was noted in the funnel plot for the primary outcome during visual examination (Figure 4). This observation was
then supported by the Egger test which detected significant publication bias within the meta-analysis (P =
0.001). We downgraded the evidence once more due to inconsistency resulting from significant statistical
heterogeneity detected within the data set. We then upgraded the evidence once for a large effect size (RR >
2.00), and once again due to the dose-response relationship demonstrated for the outcome.
We judged the evidence for the alternative efficacy outcome, seizure freedom, to be of moderate certainty. We
downgraded the evidence twice due to the very low number of events contributing to the meta-analysis, but then
upgraded once because of the large effect size (RR > 2.00) observed. Similarly, we downgraded the certainty of
evidence for the adverse effects: weight loss, paraesthesia, and difficulties with concentration, twice because
these outcomes, likewise, featured an extremely low number of events (< 100 events). For the outcome, weight
loss, we downgraded the evidence once again as a result of suspected publication bias (Egger test: P = 0.009).
We then upgraded the evidence for weight loss once due to the large effect size observed, thus producing an
overall judgement of low-certainty of evidence for this outcome. We downgraded the evidence for the outcome,
concentration difficulties, once for suspected publication bias (Egger test: P = 0.019) but then upgraded this
twice due to the very large effect size recognised (RR > 5.00). This led to an overall judgement of moderate-
certainty of evidence for concentration difficulties. We also judged the evidence for paraesthesia as being of
moderate certainty. We did not detect any publication bias in the data set (Egger test: P = 0.478), however, we
could only upgrade the evidence once back to moderate certainty as the observed effect size was large, as
opposed to very large.
In contrast, we only downgraded the evidence for the other two outcomes, treatment withdrawal and abnormal
thinking, once for imprecision. Although the number of events was insufficient to satisfy the optimal information
size, there were more events than were noted for the other outcomes (> 100 events). We then upgraded the
evidence for both outcomes back to high certainty due to the large (treatment withdrawal) and very large
(abnormal thinking) effect size revealed.
Potential biases in the review process
We strongly suspect that publication bias has impacted this review. We specifically suspect publication bias
for three of the GRADE-assessed outcomes (50% or greater seizure reduction, concentration difficulties,
and weight loss) after examining the resultant funnel plots and conducting the Egger test. Importantly,
publication bias was also suspected for the outcome, seizure freedom, however, the low number of studies
contributing data for this outcome prevented us from making a conclusive judgement regarding the funnel
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plot (Figure 5), and this was reflected in the results of the Egger test (P = 0.09).
Studies showing positive results are more likely to be published than those expressing negative results and
this consequently leads to an overestimation of the effect size (Murad 2018). It is thus possible that, in the
instance of this particular review, we have overestimated the effectiveness of topiramate compared to placebo as
an add-on therapy. Expanding the search terms in future updates could aid us in identifying any additional
unpublished data sets to help resolve this issue. Additionally, we could contact more individuals that might have
knowledge of any unpublished trials. We do, however, feel that, for the purposes of this current review update,
we have exhausted all potential sources of data. This will, however, be reassessed and further pursued for the
next review update.
Agreements and disagreements with other studies or reviews
The observations made in this review update are consistent with the previous versions of this review (Jette 2002; 
Jette 2008; Marson 1996; Marson 1997; Pulman 2014). Specifically, this review has indicated that topiramate is
efficacious as an add-on treatment for drug-resistant focal epilepsy. This review has, however, also emphasised
that treatment with topiramate remains significantly associated with certain adverse effects, including:
concentration difficulties, paraesthesia, 'thinking abnormally', and weight loss. As with the earlier versions of this
review, we are still unable to extrapolate the results to other types of epilepsy and cannot comment on the long-
term effectiveness or tolerability of topiramate as an add-on treatment.
The results of this review are also consistent with other reviews (Perucca 1997; Privitera 1997), conducted
independently of Cochrane, however, these reviews are now outdated. Notably, Perucca 1997 similarly
reported that doses of topiramate between 200 mg/day to 1000 mg/day are effective at managing drug-
resistant focal epilepsy, emphasising that even doses below 400 mg/day are likely to be beneficial. The
other review identified (Privitera 1997), likewise noted a two- to three-fold difference in the number of
people achieving 50% reduction in seizure frequency when allocated add-on topiramate compared to
placebo. Both reviews also described ataxia, concentration difficulties, paraesthesias, fatigue, dizziness,
somnolence and weight loss in their participant-reported adverse effects (Perucca 1997; Privitera 1997).
Of further significance, two of the trials included in this review explored dose-response relationships (Faught
1996; Privitera 1996). Faught 1996 considered responses at doses of 200 mg, 400 mg and 600 mg per day,
whilst Privitera 1996 evaluated responses at 600 mg, 800 mg and 1000 mg per day. Results from Faught 1996
suggest that 400 mg/day topiramate increases the likelihood of a response compared to a 200 mg/day dose, but
that no further increase is obtainable at doses of 600 mg/day. Results from Privitera 1996 also suggest little
difference in response rates between doses of 600 mg/day to 1000 mg/day. Although neither study observed an
increased response rate with doses in excess of 600 mg/day, this current review successfully demonstrated a
significant dose-response relationship whilst including all doses from 200 mg/day to 1000 mg/day. Importantly,
although the response rates were very similar for 600 mg/day and 800 mg/day, the response rate continued to
increase again when participants were randomised to the highest dose, 1000 mg/day, contrary to the reports in
these two studies.
Authors' conclusions 
Implications for practice 
Topiramate has efficacy as an add-on treatment for people with drug-resistant focal epilepsy. A daily dose of
200 mg is the lowest dose tested in the trials included in this review, and this would seem a reasonable starting
dose. The dose regression model implied additional benefit with increased dosage, however, the increase was
fairly modest. It is likely that higher doses will result in greater issues with adverse effects.
Implications for research 
To evaluate further the place of topiramate in the armamentarium of available antiepileptic drugs, further studies
are required addressing the following.
The long-term effects of add-on topiramate.1.
How topiramate compares with other add-on treatments in drug-resistant focal epilepsy.2.
The role of topiramate in childhood epilepsies.3.
How topiramate compares with standard antiepileptic drugs, such as monotherapy for focal or generalised4.
epilepsies.
The dose-response relationship with adverse effects.5.
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Differences between protocol and review 
In keeping with the previous review update, we used Mantel-Haenszel risk ratio (RR) as the preferred estimator of
treatment effect. This is in contrast to the published protocol which stated that Peto's odds ratio (OR) would be
the preferred estimator. Peto's OR is recommended for use when the event rate is very low and therefore it was
not necessary to use this estimator in this review.
In accordance with the latest classification of epilepsies published by the International League Against
Epilepsy (ILAE) (Scheffer 2017), the title of this review has been changed from 'Topiramate add-on for drug-
resistant partial epilepsy' (registered for the original review and protocol) to 'Topiramate add-on therapy for
drug-resistant focal epilepsy' (for the current update). Any reference to "partial epilepsy" or "refractory epilepsy"
throughout this review has been changed to "focal epilepsy" and "drug-resistant epilepsy", respectively.
Published notes 
Characteristics of studies
Characteristics of included studies 
Ben-Menachem 1996
Methods Double-blind, placebo-controlled, parallel-group study
2 treatment arms: 1 placebo, 1 topiramate
Pre-randomisation baseline period: 8 weeks
Treatment period: 13 weeks
 
Participants A multicentre study (Sweden, Norway, Denmark, Germany)
56 people randomised (all with drug-resistant focal epilepsy): 28 to placebo
and 28 to 800 mg topiramate
Age range: 18 to 65 years
Mean age: 37.2 years
84% males
Other AEDs: 2 or fewer
Median baseline monthly seizure frequency: 11.4 for placebo group, 14.2 for
topiramate group
 
Interventions 800 mg topiramate per day or placebo
 
Outcomes Percentage reduction in generalised seizure rate1.
Percentage responders (50% and 75%)2.
Adverse effects3.
 
Notes Trial sponsored by Johnson & Johnson
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "computer-generated randomization schedule"




Low risk Comment: sealed, numbered packages allocated sequentially
 
Blinding (performance bias and
detection bias)
Low risk Comment: identical tablets and packaging
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: it is likely that blinding was maintained due to the
methods used
 
Blinding of outcome assessment
(detection bias)










Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
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Methods Double-blind, placebo-controlled, parallel-group study
2 treatment arms: 1 placebo, 1 topiramate
Pre-randomisation baseline period: 8 weeks
Treatment period: 11 weeks
 
Participants A multicentre study (Argentina, Australia, Belgium, Canada, Chile, Germany,
Greece, Hungary, India, Israel, New Zealand, Poland, Russia, South Africa,
Spain, and USA)
249 people randomised (all with drug-resistant focal epilepsy): 125 to placebo
and 124 mg to 200 mg per day topiramate
Age range: 18 to 75 years
Mean age: 37.6 years
53% males
Other AEDs: 1 or more
Median baseline seizure frequency/week: 2.7 for placebo group, 2.3 for
topiramate group
 
Interventions 200 mg topiramate per day or placebo
 
Outcomes Primary outcome: median percentage reduction in weekly partial onset seizure
frequency
Secondary outcomes:
responder rate (≥ 50% reduction in seizure frequency)1.
seizure freedom rate2.
clinician-reported Global Impression of Change (CGI-C)3.
patient-reported Quality of Life in Epilepsy–Problems (QOLIE-31-P) survey4.
adverse events5.
safety and tolerability outcomes including laboratory parameters, neurology6.
and physical examination, vital signs, and electrocardiography
 
Notes Trial sponsored by Upsher-Smith Laboratories, Inc
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Randomization by an independent statistician was





Low risk Quote: "The interactive voice response group programmed the
randomization schedule for investigators to dispense study
drug."
 
Blinding (performance bias and
detection bias)
Low risk Quote: "matching placebo"
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: it is likely that blinding was maintained
 
Blinding of outcome assessment
(detection bias)





Low risk Comment: no concerns about missing data





Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
 
Other bias Low risk Comment: the study appears to be free of other sources of bias
 
Elterman 1999
Methods Randomised, double-blind, placebo-controlled, parallel-group study
2 treatment arms: 1 placebo, 1 topiramate
Pre-randomisation baseline period: 8 weeks
Treatment period: 16 weeks
 
Participants A multicentre study (USA, Costa Rica)
86 people were randomised (all with drug-resistant focal epilepsy): 45 to
placebo and 41 to topiramate
Age range: 2 to 16 years
Mean age: 9.0 years for placebo group, 8.8 years for topiramate group
56% males
Other AEDs: 2 or fewer, except for person who was on more than 2 AEDs
Median baseline monthly seizure frequency: 19 for placebo group, 22 for
topiramate group (focal-onset seizures)
 
Interventions 6 mg/kg/day topiramate or placebo
 
Outcomes Primary outcome:
median percentage reduction in average monthly focal-onset seizure rate
Secondary outcomes:
median percentage reduction in average monthly seizure rate for1.
secondarily generalised seizures




Notes Trial sponsored by Johnson & Johnson
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Risk of bias table
Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Low risk Comment: sealed, numbered packages allocated sequentially
 
Blinding (performance bias and
detection bias)
Low risk Quote: "tablets that were similar in shape, size and color"
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: it is likely that blinding was maintained
 
Blinding of outcome assessment
(detection bias)










Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
 




Methods Double-blind, placebo-controlled, parallel-group study
4 treatment arms: 1 placebo, 3 topiramate
Pre-randomisation baseline period: 12 weeks
Treatment period: 16 weeks
 
Participants A multicentre study (USA)
181 people were randomised (all with drug-resistant focal epilepsy): 45 to
placebo, 45 mg to 200 mg per day topiramate, 45 mg to 400 mg per day
topiramate, 46 mg to 600 mg per day topiramate
Age range: 19 to 68 years
Mean age: 36.9 years
Other AEDs: 2 or fewer
70% males
Median baseline monthly seizure frequency: 10.8 (10.0 for placebo group,
11.5 for 200 mg/d topiramate group, 11.0 for 400 mg/d topiramate group,
11.2 for 600 mg/d topiramate group)
 
Interventions 200 mg topiramate per day or 400 mg topiramate per day or 600 mg
topiramate per day or placebo
 




Notes Trial sponsored by Johnson & Johnson
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Low risk Comment: sealed, numbered packages allocated sequentially
 
Blinding (performance bias and
detection bias)
Low risk Comment: identical tablets and packaging
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: it is likely that blinding was maintained
 
Blinding of outcome assessment
(detection bias)





Low risk Comment: no concerns about missing data




Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
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Methods Randomised, double-blind, placebo-controlled study
3 treatment arms: 1 placebo, 2 topiramate
Pre-randomisation baseline period: 4 weeks
Treatment period: 12 weeks
 
Participants A multicentre study (Hungary, Poland, Israel, Canada, Russia, Czech Republic)
263 people were randomised (all with drug-resistant focal epilepsy): 91 to
placebo, 85 to topiramate escalated weekly by 25 mg/day to 200 mg/day, 83
to topiramate escalated weekly by 50 mg/day to 200 mg/day
Age range: 18 to 67 years for placebo group, 18 to 64 years for topiramate
groups
Mean age: 36 years for placebo group, 37 years for topiramate groups
50% males for placebo group, 46% males for topiramate groups
Other AEDs: 2 or fewer
Median baseline monthly seizure frequency: 7 for placebo group, 7 for
topiramate group
 
Interventions 200 mg topiramate per day escalated over 8 weeks by 25 mg/day increases
weekly or 200 mg topiramate per day escalated over 4 weeks by 50 mg/day
increases weekly or placebo
 
Outcomes Primary outcome:
medial % reduction from baseline in monthly focal-onset seizure frequency for
the combined topiramate groups versus placebo group
Secondary outcomes:
responder rate (50% reduction in seizure frequency)1.
adverse effects2.
other safety evaluation outcomes including clinical laboratory evaluations,3.
neurology and physical examination, vital signs, and body weight
measurements
 
Notes Trial sponsored by Johnson & Johnson
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Unclear risk Quote: "randomized in equal proportions"
Comment: insufficient information provided to determine




Unclear risk Comment: details regarding allocation concealment were not
provided
 
Blinding (performance bias and
detection bias)
Low risk Comment: identical tablets and packaging
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: it is likely that blinding was maintained
 
Blinding of outcome assessment
(detection bias)










Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
 
Other bias Low risk Comment: the study appears to be free of other sources of
bias
 
Korean Topiramate Study Group 1999
Methods Randomised, double -blind, placebo -controlled study
2 treatment arms: 1 placebo, 1 topiramate
Pre-randomisation baseline period: 12 weeks
Treatment period: 18 weeks
 
Participants A multicentre study (Korea)
177 people were randomised (all with drug-resistant focal epilepsy): 86 to
placebo, 91 to topiramate
Age range: 16 to 65 years
Mean age: 29.8 years for placebo group, 29.6 years for topiramate group
54% males
Other AEDs: 2 or fewer
Median baseline monthly seizure frequency: 5.6 for placebo group, 5.6 for
topiramate group
 
Interventions 600 mg topiramate per day or placebo
 
Outcomes Median seizure frequency reduction rate1.
Responder rate2.
Seizure-free rate3.
Global evaluation by participant and physician4.
Adverse effects5.
 
Notes Trial sponsored by Janssen Korea Ltd
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Low risk Comment: sealed, numbered packages allocated sequentially
 
Blinding (performance bias and
detection bias)
Low risk Comment: identical tablets and packaging
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: it is likely that blinding was maintained
 
Blinding of outcome assessment
(detection bias)





Low risk Comment: 2 patients in the topiramate group and 1 in the
placebo group were excluded from the analysis. It was
determined that this did not represent a potentially clinically
important impact
Quote: "intention-to-treat analysis (ITTA) was performed for




Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
 
Other bias Low risk Comment: the study appears to be free of other sources of bias
 
Privitera 1996
Methods Double-blind, parallel-group study
4 treatment arms: 1 placebo, 3 topiramate
Pre-randomisation baseline period: 12 weeks
Treatment period: 18 weeks
 
Participants A multicentre study (USA)
190 people were randomised (all with drug-resistant focal epilepsy): 47 to
placebo, 48 to 600 mg topiramate, 48 to 800 mg topiramate, 47 to 1000 mg
topiramate
Age range: 18 to 68 years
Mean age: 35.5 years
80% males
Other AEDs: 2 or fewer
Median baseline monthly seizure frequency: 11 (9.3 for placebo group, 10.0
for 600 mg/d topiramate group, 16.2 for 800 mg/d topiramate group, 11.7
for 1000 mg/d topiramate group)
 
Interventions 600 mg topiramate per day or 800 mg topiramate per day or 1000 mg
topiramate per day or placebo
 
Outcomes Percentage seizure rate reduction1.
Percentage responders (≥ 50%)2.
Adverse effects3.
 
Notes Trial sponsored by Johnson & Johnson
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Low risk Comment: sealed, numbered packages allocated sequentially
 
Blinding (performance bias and
detection bias)
Low risk Quote: "topiramate and placebo tablets were identical in
appearance and packaging"
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: it is likely that blinding was maintained
 
Blinding of outcome assessment
(detection bias)





Low risk Quote: "all 209 subjects who enrolled in the double-blind




Low risk Comment: data published in full according to the protocol
 




Methods Double-blind, placebo-controlled, parallel-group study
2 treatment arms: 1 placebo, 1 topiramate
Prospective pre-randomisation baseline period: 8 weeks
Treatment period: 19 weeks
 
Participants A multicentre study (USA)
209 people were randomised (all with drug-resistant focal epilepsy): 42 to
placebo, 167 to 1000 mg topiramate




Baseline seizure frequency (unknown). Patients had to have a minimum of 6
focal seizures during the 8-week baseline phase
 
Interventions 1000 mg topiramate per day or placebo
 
Outcomes Proportion with a 50% reduction in seizure frequency
 
Notes Limited information regarding trial. All information was provided by a single
poster abstract.
Trial sponsored by Johnson & Johnson
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Low risk Comment: sealed, numbered packages allocated sequentially
 
Blinding (performance bias and
detection bias)
Low risk Quote: "tablets were identical in appearance and packaging"
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: only states "double-blinded", and so blinding is
likely though not confirmed
 
Blinding of outcome assessment
(detection bias)










Low risk Comment: appears all expected and prespecified outcomes
are reported
 




Methods Randomised, double-blind, placebo-controlled, parallel-group study
2 treatment arms: 1 placebo, 1 topiramate
Pre-randomisation baseline period: 8 weeks
Treatment period: 11 weeks
 
Participants A multicentre study (Sweden, Spain, UK and France)
47 people were randomised (all with drug-resistant focal epilepsy): 24 to
placebo, 23 to 400 mg topiramate
Age range: 18 to 65 years
Mean age: 34 years
85% males
Other AEDs: 2 or fewer
Median baseline monthly seizure frequency: 12.5 (10 for placebo group, 18
for topiramate group)
 
Interventions 400 mg topiramate per day or placebo
 




Notes Trial sponsored by Johnson & Johnson
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Comment: random permuted blocks




Low risk Comment: sealed, numbered packages allocated sequentially
 
Blinding (performance bias and
detection bias)
Low risk Comment: identical tablets and packaging
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: patients and clinical staff blinded
 
Blinding of outcome assessment
(detection bias)




Low risk Comment: no participants were excluded from the analysis




Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
 




Methods Double-blind, placebo-controlled, parallel-group study
2 treatment arms: 1 placebo, 1 topiramate
Pre-randomisation baseline period: 8 weeks
Treatment period: 12 weeks
 
Participants A multicentre study (UK, Italy, France, Norway and Denmark)
60 people were randomised (all with drug-resistant focal epilepsy): 30 to
placebo 30 to 600 mg topiramate
Age range: 18 to 65 years
Mean age: 32.9 years
68% males
Other AEDs: 2 or fewer
Median baseline monthly seizure frequency: 15.0 for placebo group, 16.8 for
topiramate group
 
Interventions 600 mg topiramate per day or placebo
 
Outcomes Percentage reduction in average seizure rate1.
Percentage responders (patients with 50% reduction in seizure rate)2.
Adverse effects3.
 
Notes Trial sponsored by Johnson & Johnson
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)




Low risk Comment: sealed, numbered packages allocated sequentially
 
Blinding (performance bias and
detection bias)
Low risk Quote: "topiramate and placebo tablets were identical"
 
Blinding of participants and
personnel (performance bias)
Low risk Comment: it is likely that blinding was maintained
 
Blinding of outcome assessment
(detection bias)










Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
 




Methods Double-blind, placebo-controlled, parallel-group
2 treatment arms: 1 placebo, 1 topiramate
Pre-randomisation baseline period: 8 weeks
Treatment period: 14 weeks
 
Participants A single-centre study (China)
46 people were randomised (all with drug-resistant focal epilepsy): 23 to
placebo, 23 to topiramate
Age range: 18 to 54 years
Mean age: 32.0 years for placebo group, 31.4 years for topiramate group
41% males
Other AEDs: up to 4 or more
Median baseline monthly seizure frequency: 5 to 10 for placebo group, < 5 for
topiramate group
 
Interventions 300 mg topiramate per day or placebo
 





Notes Trial sponsored in part by grants from Taipei Veterans General Hospital (88-
V229) and the Yen Tjing Ling Medical Foundation
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Comment: random permuted blocks




Low risk Comment: sealed, numbered packages allocated sequentially
 
Blinding (performance bias and
detection bias)
Low risk Quote: "matching placebo tablets"
 
Blinding of participants and
personnel (performance bias)
Low risk Quote: "investigators, patients, study monitors and observers
remained blinded to codes"
 
Blinding of outcome assessment
(detection bias)
Low risk Quote: "investigators, patients, study monitors and observers




Low risk Quote: "intention-to-treat efficacy analysis"




Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
 




Methods Randomised, placebo-controlled trial
2 treatment arms: 1 placebo, 1 topiramate
Pre-randomisation baseline period: 8 weeks
Treatment period: 12 weeks
 
Participants A single-centre study (Shanghai, China)
86 participants were randomised (documented drug-resistant focal epilepsy)
Age range: > 65 years old eligible
Mean age: 73.4 years
57% males
8 patients on 1 AED, 37 on 2 AEDs, 41 on 3 AEDs
Median baseline monthly seizure frequency: 17.3 for placebo group, 16.9 for
topiramate group
 
Interventions 200 mg per day topiramate or placebo
 
Outcomes Percentage seizure reduction (≥ 50% reduction (classified as responders);1.






No trial sponsorship information provided
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Random sequence generation
(selection bias)





Unclear risk Comment: no information provided
 
Blinding (performance bias and
detection bias)
Unclear risk Comment: no information provided
 
Blinding of participants and
personnel (performance bias)
Unclear risk Comment: no information provided
 
Blinding of outcome assessment
(detection bias)








Low risk Comment: protocol unavailable, but appears all expected and
prespecified outcomes are reported
 





Characteristics of excluded studies 
Christensen 2003
Reason for exclusion Alternative dose-controlled study, no placebo control group
 
Chung 2009
Reason for exclusion Active comparator-controlled study, no placebo control group
 
Coles 1999
Reason for exclusion Study did not investigate outcomes of interest: 50% or greater reduction in
seizure frequency, treatment withdrawal or adverse effects. Studied seizure
severity as outcome using seizure severity scales
 
Novotny 2010
Reason for exclusion Baseline period too short (48 hours)
 
Ramsay 2008
Reason for exclusion Alternative dose-controlled study, no placebo control group
 
Footnotes
Characteristics of studies awaiting classification 
Aranguiz 1991
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Methods A double-blind, parallel, placebo-controlled study
 
Participants Patients with drug-resistant focal seizures
 









Participants 45 patients aged 12 to 51 with simple focal seizures or complex focal
seizures, with or without secondary generalisation receiving 1 to 4 AEDs
 
Interventions Added tiagabine in 19 patients, gabapentin in 10 patients and topiramate in
16 patients to the previous treatment
 
Outcomes Efficacy was evaluated as: seizure-free, improvement of at least 50%, no
improvement, worsening. Results of treatment were as follows.
Seizure-free: tiagabine (3 cases, 15.9%), gabapentin (1 case, 10%),1.
topiramate (2 cases, 12.5%)
Improvement of at least 50%: tiagabine (9 cases, 47.3%), gabapentin (22.
cases, 20%), topiramate (8 cases, 50%)
No improvement: tiagabine (6 cases, 31.5%), gabapentin (7 cases, 70%),3.
topiramate (5 cases, 31.25%)






RCT: randomised controlled trial
Characteristics of ongoing studies 
Footnotes
Summary of findings tables
1 Topiramate compared to placebo for drug-resistant focal epilepsy
Add-on topiramate compared to placebo for drug-resistant focal epilepsy
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50% or greater reduction in seizure
frequency (ITT analysis)
Follow-up: range 11 to 19 weeks





















Follow-up: range 11 to 19 weeks



















Follow-up: range 11 to 19 weeks














Adverse effects - weight
loss/decrease
Follow-up: range 11 to 18 weeks



















Adverse effects - paraesthesia
Follow-up: range 11 to 18 weeks



















Adverse effects - 'thinking
abnormally'
Follow-up: range 12 to 19 weeks





















Follow-up: range 11 to 18 weeks


















*The risk in the intervention group (and its 95% or 99% confidence interval, dependent on the outcome) is based
on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% or 99% CI,
dependent on the outcome).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the
estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from
the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be
substantially different from the estimate of effect.
Footnotes
aWe did not downgrade evidence for risk of bias; we judged risk of bias across studies to be low. Ten studies did
not describe the blinding of outcome assessors, one study failed to explain randomisation and allocation
concealment and another did not describe any method of blinding. We, however, reasoned that the blinding of
outcome assessors would minimally impact the estimated effect size due to the self-reported nature of the
review outcomes.
bWe downgraded the evidence once for inconsistency: we detected significant statistical heterogeneity.
cWe downgraded the evidence once for publication bias: examination of funnel plot and Egger test indicates the
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possibility of publication bias.
dWe downgraded the evidence once for imprecision: the number of events (< 400) did not suffice optimal
information size.
eWe downgraded the evidence twice for imprecision: the number of events (< 100) did not suffice optimal
information size.
fWe upgraded the evidence once for large effect: RR > 2.00.
gWe upgraded the evidence twice for large effect: RR > 5.00.
















Sweden, Norway, Denmark, Germany Adults 1 to 2 56 8 weeks 13 weeks
Chung 2014
Argentina, Australia, Belgium,
Canada, Chile, Germany, Greece,
Hungary, India, Israel, New Zealand,
Poland, Russia, South Africa, Spain,
USA
Adults 1 to ≥7 249 8 weeks 11 weeks
Elterman 1999 USA, Costa Rica Children 1 to 2 86 8 weeks 16 weeks
Faught 1996 USA Adults 1 to 2 181 12 weeks 16 weeks
Guberman 2002 Hungary, Poland, Israel, Canada,
Russia, Czech Republic





Korea Adults 1 to 2 177 12 weeks 18 weeks
Privitera 1996 USA Adults 1 to 2 190 12 weeks 18 weeks
Rosenfeld 1996 USA Adults 1 209 8 weeks 19 weeks
Sharief 1996 Sweden, Spain, UK, France Adults 1 to 2 47 8 weeks 11 weeks
Tassinari 1996 UK, Italy, France, Norway, Denmark Adults 1 to 2 60 8 weeks 12 weeks
Yen 2000 China Adults 1 to 4 46 8 weeks 14 weeks
Zhang 2011 China Elderly 1 to 3 86 8 weeks 12 weeks
Footnotes
AED: antiepileptic drug
2 Estimated response rates per dose and percentage difference in responders per dose compared to
placebo
Dose (mg)Fitted response rate (%)
95% CI




Placebo 17.8 6.3 29.4
200 37.6 20.2 55.0 200 19.7 -1.2 40.6
300 38.1 -28.1 104.2 300 20.2 -46.9 87.3
400 37.5 7.8 67.3 400 19.7 -12.2 51.6
450 38.1 -16.1 92.4 450 20.3 -35.2 75.8
600 42.2 23.5 61.0 600 24.4 2.4 46.5
800 42.2 13.8 70.6 800 24.4 -6.3 55.1
1000 51.1 29.5 72.7 1000 33.3 8.8 57.8
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1.1 50% reduction in seizure
frequency - Sensitivity analysis
by study quality
3 283 Risk Ratio(M-H, Fixed, 95% CI) 4.36 [2.24, 8.50]
1.2 50% reduction in seizure
frequency - ITT analysis 12 1650 Risk Ratio(IV, Random, 95% CI) 2.71 [2.05, 3.59]
1.3 50% reduction in seizure
frequency - Sensitivity analysis
by patient characteristics (age)
11 1564 Risk Ratio(IV, Random, 95% CI) 2.85 [2.09, 3.88]
1.4 50% reduction in seizure
frequency - Sensitivity analysis
by intervention (dosage)
9 1052 Risk Ratio(M-H, Fixed, 95% CI) 3.32 [2.51, 4.38]
1.5 50% reduction in seizure
frequency - Best-case analysis 12 1650 Risk Ratio(IV, Random, 95% CI) 3.54 [2.67, 4.69]
1.6 50% reduction in seizure
frequency - Worst-case analysis 12 1650 Risk Ratio(IV, Random, 95% CI) 1.96 [1.54, 2.50]
1.7 Seizure freedom 8 1177 Risk Ratio(M-H, Fixed, 95% CI) 3.67 [1.79, 7.54]
1.8 Treatment withdrawal 12 1650 Risk Ratio(M-H, Fixed, 95% CI) 2.37 [1.66, 3.37]
1.9 Adverse effects 12   Risk Ratio(M-H, Fixed, 99% CI) Subtotals only
   1.9.1 Ataxia 4 757 Risk Ratio(M-H, Fixed, 99% CI) 2.29 [1.10, 4.77]




6 702 Risk Ratio(M-H, Fixed, 99% CI) 7.81 [2.08, 29.29]
   1.9.3 Dizziness 8 1385 Risk Ratio(M-H, Fixed, 99% CI) 1.52 [1.07, 2.16]
   1.9.4 Fatigue 10 1427 Risk Ratio(M-H, Fixed, 99% CI) 2.08 [1.37, 3.15]
   1.9.5 Headache 9 1092 Risk Ratio(M-H, Fixed, 99% CI) 0.96 [0.67, 1.39]
   1.9.6 Nausea/vomiting 4 492 Risk Ratio(M-H, Fixed, 99% CI) 1.50 [0.71, 3.15]
   1.9.7 Paraesthesia 7 1071 Risk Ratio(M-H, Fixed, 99% CI) 3.65 [1.58, 8.39]
   1.9.8 Somnolence 9 1462 Risk Ratio(M-H, Fixed, 99% CI) 2.44 [1.61, 3.68]
   1.9.9 Speech
difficulties/language problems 3 310 Risk Ratio(M-H, Fixed, 99% CI) 3.37 [0.80, 14.13]
   1.9.10 Thinking abnormally 4 640 Risk Ratio(M-H, Fixed, 99% CI) 5.70 [2.26, 14.38]
   1.9.11 Weight loss/decrease 9 1070 Risk Ratio(M-H, Fixed, 99% CI) 3.99 [1.82, 8.72]
Figures
Figure 1
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Caption
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
Figure 3
Caption
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all
included studies.
Figure 4 (Analysis 1.2) 
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Caption
Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.2 50% reduction in seizure frequency - ITT
analysis.
Figure 5 (Analysis 1.7) 
Caption
Funnel plot of comparison: 1 Topiramate versus placebo, outcome: 1.7 Seizure freedom.
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1 CRS Web search strategy
1. Topiram* or Tipiram* or Topamax or TPM or Qudexy AND CENTRAL:TARGET
2. (monotherap* not (adjunct* or "add-on" or "add on" or adjuvant* or combination* or polytherap*)):TI AND
CENTRAL:TARGET
3. #1 NOT #2
4. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
5. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
6. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
7. #4 OR #5 OR #6 AND CENTRAL:TARGET
8. #7 AND #3
2 MEDLINE search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials
(Lefebvre 2011).
1. (Topiram$ or Tipiram$ or Topamax or TPM or Qudexy).tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo
or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. (monotherap$ not (adjunct$ or "add-on" or "add on" or adjuvant$ or combination$ or polytherap$)).ti.
16. 14 not 15
17. remove duplicates from 16
3 ClinicalTrials.gov search strategy
Interventional Studies | Epilepsies, Partial | Topiramate OR Topamax or TPM or Qudexy
4 WHO International Clinical Trials Registry Platform (ICTRP) search strategy
partial epilepsy OR focal epilepsy in the Condition AND
Topiramate OR Topamax OR TPM OR Qudexy in the Intervention
5 SCOPUS search strategy
((TITLE(Topiramate or Topamax) OR ABS(Topiramate or Topamax)) AND (TITLE((randomiz* OR randomis* OR
controlled OR placebo OR blind* OR unblind* OR "parallel group" OR crossover OR "cross over" OR cluster OR
"head to head") PRE/2 (trial OR method OR procedure OR study)) OR ABS((randomiz* OR randomis* OR controlled
OR placebo OR blind* OR unblind* OR "parallel group" OR crossover OR "cross over" OR cluster OR "head to
head") PRE/2 (trial OR method OR procedure OR study))) AND ((TITLE-ABS-KEY(epilep* OR "infantile spasm" OR
seizure OR convuls* OR (syndrome W/2 (aicardi OR angelman OR doose OR dravet OR janz OR jeavons OR
"landau kleffner" OR "lennox gastaut" OR ohtahara OR panayiotopoulos OR rasmussen OR rett OR "sturge weber"
OR tassinari OR "unverricht lundborg" OR west)) OR "ring chromosome 20" OR "R20" OR "myoclonic
encephalopathy" OR "pyridoxine dependency") AND NOT (TITLE(*eclampsia) OR INDEXTERMS(*eclampsia))) OR
(TITLE-ABS-KEY(lafora* W/4 (disease OR epilep*)) AND NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR
canine))))) AND NOT (TITLE(monotherap* AND NOT (adjunct* OR "add-on" OR "add on" OR adjuvant* OR
combination* OR polytherap*)))
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